When the same genetic variants that regulate circulating proteins also associate with disease risk, researchers gain powerful causal leverage — a shortcut past decades of failed drug programs. This study delivers that leverage at unprecedented scale, and the implications for how future medicines are discovered and repurposed are substantial.
Drawing on 78,664 participants across 38 independent cohorts, this proteogenomic meta-analysis is the largest of its kind by a considerable margin. The investigators catalogued more than 24,000 protein quantitative trait loci (pQTLs) influencing 1,116 plasma proteins, partitioning them into cis-pQTLs — variants acting near the gene encoding the protein itself (5,040 signals) — and trans-pQTLs, which act at a genomic distance (19,698 signals). Machine learning was applied to assign likely effector genes, revealing N-linked glycosylation as a previously underappreciated regulatory hub governing circulating protein levels. Critically, the analysis demonstrates that cis- and trans-pQTLs carry distinct biological information: cis instruments speak to protein production and intrinsic function, while trans instruments illuminate broader modulatory networks. Triangulating these signals with disease associations flagged plasma furin as a cardiovascular drug target candidate and provided genetic support for repurposing TYK2 inhibitors — already used in dermatology — toward rheumatoid arthritis.
Proteome-wide association studies and pQTL mapping have accelerated sharply since SomaScan and Olink multiplexing platforms matured, but most prior atlases covered fewer than 30,000 participants or far fewer proteins. This study's scale is genuinely paradigm-expanding: the trans-pQTL triangulation framework offers a systematic drug-repurposing engine grounded in human genetic causality, not observational correlation. The main limitation is that circulating plasma proteins represent a filtered snapshot — tissue-level and intracellular biology remain largely invisible. Replication across ancestry-diverse cohorts will also be necessary, as most participating studies skew European. Still, for longevity and precision medicine audiences, the furin-cardiovascular axis and TYK2 repurposing signal alone represent clinically actionable leads worthy of close follow-up.